Research Interest: Primary: Kidney (patho-)physiology Secondary: Diabetes mellitus, oxidative stress, ion transport

My name is Karthik Yadav Janga and I am currently working as Research Scientist in Novel Drug Delivery team at Bayer Pharmaceuticals (USA). I am writing this email in order to volunteer for joining the editorial board member and peer reviewer for your prestigious journal. I have published 23 research articles in renowned journals such as European Journal of Pharmaceutics and Biopharmaceutics and International Journal of Pharmaceutics etc, with over 273 citations. 8+ (academic and industrial) years research experiences in the field of pharmaceutics and drug delivery.

Research Interest: Drug delivery of NCEs, Protein, Peptides, Monoclonal antibodies

Grants: Research Scholar in NIH R01 grant

URL: https://scholar.google.com/citations?user=xZ4Z2wkAAAAJ&hl=en

List of Publications:

1.  Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation. N Dudhipala, KY Janga. Drug Dev Ind Pharm. 2017; 43(7): 1205-1214.

2.  Biopharmaceutical and Preclinical Studies of Zaleplon as Semisolid Dispersions with Self-emulsifying Lipid Surfactants for Oral Delivery. N Dudhipala, A Narala, D Suram, KY Janga. IJPSN. 2016; 9(1): 3102-3111. (Best Paper of the Year Award)

3.  Competence of raloxifene hydrochloride loaded liquisolid compacts for improved dissolution and intestinal permeation. DR Komala, KY Janga, R Jukanti, S Bandari, M Vijayagopal. J Drug Deliv Sci Technol. 2015; 30(A): 232-241. Main Author

4.  Gellan gum based sol-to-gel transforming system of natamycin transfersomes improves topical ocular delivery. KY Janga, A Tatke, N Dudhipala, SP Balguri, MM Ibrahim, DN Maria, MM Jablonski, S Majumdar. JPET. Mar 14, 2019. DOI: https://doi.org/10.1124/jpet.119.256446

5.  Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation. KY Janga, A Tatke, SP Balguri, SP Lamichanne, MM Ibrahim, DN Maria, MM Jablonski, S Majumdar. Artif Cells Nanomed Biotechnol. 2018; 46(1): 1039-1050.

6.  Retina compatible interactions and effective modulation of blood ocular barrier P-gp activity by third-generation inhibitors improve the ocular penetration of loperamide. KY Janga, A Tatke, S Shukla, SP Lamichhane, B Avula, X Wang, MM Jablonski, IA Khan, S Majumdar. J Pharm Sci. 2018; 107(8): 2128-2135.

7.  Photostability Issues in Pharmaceutical Dosage Forms and Photostabilization. KY Janga, T King, N Ji, S Sarabu, G Shadambikar, S Sawant, P Xu, MA Repka, SN Murthy. AAPS PharmSciTech. 2018; 19(1): 48-59.

8.  P-glycoprotein restricts ocular penetration of loperamide across the blood-ocular barriers: a comparative study in Mdr1a knock-out and wild type sprague dawley rats. A Tatke, KY Janga, B Avula, X Wang, MM Jablonski, IA Khan, S Majumdar. AAPS PharmSciTech. 2018; 19(4): 1662-1671.

9.  In situ absorption and relative bioavailability studies of zaleplon loaded self-nanoemulsifying powders. KY Janga, R Jukanti, S Sunkavalli, A Velpula, S Bandari, P Kandadi, PR Veerareddy. J Microencapsul. 2013; 30(2): 161-172.

10.  Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. KY Janga, R Jukanti, A Velpula, S Sunkavalli, S Bandari, P Kandadi, PR Veerareddy. Eur J Pharm Biopharm. 2012; 80(2): 347-357.

11.  Melt-cast films significantly enhance triamcinolone acetonide delivery to the deeper ocular tissues. A Tatke, N Dudhipala, KY Janga, B Soneta, B Avula, S Majumdar. Pharmaceutics. 2019; 11(4): 158.

12.  In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: Tear kinetics and ocular disposition studies. A Tatke, N Dudhipala, KY Janga, SP Balguri, B Avula, M Jablonski, S Majumdar. Nanomaterials. 2019; 9(1): 33.

13. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. N Dudhipala, KY Janga, T Gorre. Artif Cells Nanomed Biotechnol. 2018; 46(2): 616-625.

14. Micronized zaleplon delivery via orodispersible film and orodispersible tablets. P Manda, C Popescu, A Juluri, KY Janga, PR Kakulamarri, S Narishetty, SN Murthy, MA Repka. AAPS PharmSciTech. 2018; 19(3): 1358-1366.

15. Melt-cast noninvasive ocular inserts for posterior segment drug delivery. SP Balguri, GR Adelli, A Tatke, KY Janga, P Bhagav, S Majumdar. J Pharm Sci. 2017;106(12): 3515-3523.

16. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol. SP Balguri, GR Adelli, KY Janga, P Bhagav, S Majumdar. Int J Pharm. 2017; 529(1-2): 32-43.

17. Preparation and characterization of docetaxel self-nanoemulsifying powders (SNEPs): A strategy for improved oral delivery. S Sunkavalli, BB Eedara, KY Janga, A Velpula, R Jukanti, S Bandari. KOREAN J CHEM ENG. 2016; 33(3): 1115–1124.

18. Amoxycillin trihydrate floating-bioadhesive drug delivery system for eradication of Helicobacter pylori: Preparation, in vitro and ex vivo evaluation. N Dudhipala, A Narala, KY Janga, R Bomma. J Bioequiv Availab. 2016; 8(3): 118-124.

19. Enhanced dissolution efficiency of zaleplon solid dispersions via modified β-cyclodextrin molecular inclusion complexes. C Popescu, P Manda, A Juluri, KY Janga, M Cidda, SN Murthy. J. Pharm Pharm Scien. 2015; 1(1): 12-21.

20. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. A Velpula, R Jukanti, KY Janga, S Sunkavalli, S Bandari, P Kandadi, PR Veerareddy. Drug Dev Ind Pharm. 2013; 39(12): 1895-1906.

21. Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. M Burraa, R Jukanti, KY Janga, S Sunkavalli, A Velpula, S Ampati, KN Jayaveera. ADV POWDER TECHNOL. 2013; 24(1): 393-402.

22. Development and characterization of ramipril loaded Solid self nanoemulsifying drug delivery system (SNEDDS) for improved oral delivery of lipophilic drugs. M Kasturi, S Agrawal, KY Janga. IJPBA. 2015; 6(6): 10-17.

23. Self nano emulsifying drug delivery system of ramipril: formulation and in vitro evaluation. M Kasturi, S Agrawal, KY Janga. Int J Pharm Pharm Sci. 2016; 8(4): 291-296.

Research Interest: Reproductive science, Antioxidant potential of some peptides: oxytocin, melatonin, kisspeptin, Neurosicence, Ischemia/reperfusion injury, Reproductive science, Antioxidant potential of some peptides: oxytocin, melatonin, kisspeptin, NeurosicenceIschemia/reperfusion injury

Research Interest: Genetic disorder, splicing mutations, Cornelia de Lange Syndrome, HMG-CoA lyase deficiency, HMG-CoA synthase deficiency

Research Interest: Diabetes, Adrenal Insufficiency, Evidence-Based Medicine in Endocrinology

Research Interest: General Physiology, Endocrine Physiology, Neuroendocrine Regulation of Body Weight, Epidemiology of Obesity and Diabetes, Endocrinology, Exercise Effect Evaluation

Research Interest: Osteoporosis, Autophagy, Osteocyte, Mechanism.

Research Interest: Endocrinology, endocrine disorders, developmental endocrinology, endocrine pathophysiology/issues, endocrine disorders complications treatment/management.

Research Interest: Andrological Sciences.

Research Interest: Diabetes,  transplantation,  pancreatic islets culture, influence of microorganism on onset of the diabetes, human microbiom.

Research Interest: clinical and genetics of metabolic bone diseases; clinical and genetics of familial and sporadic neuroendocrine tumors.

Grants: • 1992 Grant Meeting: "International Conferences On Calcium Regulating Hormones, Florence, 24 to 29 April 1992. Awarded by the Scientific Program Committee and Executive Committee.

• 2009: Lifetime Career Achievement Award of the Italian Society of Osteoporosis and Mineral Metabolism and Disease of the Skeleton, Torino, November 20, 2009.

URL: ORCID ID https://orcid.org/0000-0002-6739-4417;

List of Publications:
PUBBLICAZIONI SU RIVISTE INTERNAZIONALI

1.    de Leonardis V., De Scalzi M., Falchetti A., Cinelli P., Croppi E., Livi R., Scarpelli L., Scarpelli P.T.: Echocardiographic evaluation of children with and without family hystory of essential hypertension. Am. J. Hypert. 1:305-308, 1988. [IF 3.496; 2005]

2.    de Leonardis V., De Scalzi M., Perrin A., Falchetti A., Cinelli P.: Systolic time intervals and their relationship to arterial blood pressure. J. Hypert. 4 (suppl. 5): S319-S321, 1986. [IF 5.218; 2005]

3.    Friedman E, Sakaguchi K., Bale A.E., Falchetti A., Streeten E., Zimering M., Weinstein L., Mc Bride W.O., Nakamura Y., Brandi M. L., Norton J. A., Aurbach G. D., Spiegel A. M., Marx S. J.: Parathyroid tumors in familial multiple endocrine neoplasia type 1 and in sporadic adenomas show clonal losses of alleles within chromosome 11. New Engl. J. Med. 321, 213, 1989. [44.016; 2005]

4.    Falchetti A., Bale A. E., Amorosi A., Bordi C., Cicchi P., Bandini S., Marx S. J., Brandi M. L.: Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J. Clin. End. Metab. 76: 139, 1993. [6.02, 2005]

5.    Brandi M.L., Weber G., Svensson A., Falchetti A., Tonelli F., Castello R., Furlani L., Scappaticci S., Fraccaro M., Larsson C. Homozygotes for the autosomal dominant neoplasia syndrome (MEN I). Am J Hum Genet. 53:1167-1172, 1993. [12.649; 2005]

6.    Bani Sacchi T., Bani D., Brandi M.L., Falchetti A., Bigazzi M. Relaxin influences growth, differentiation and cell-cell adhesion of human breast-cancer cells in culture. Int J Cancer. 57:129-134, 1994. [4.7; 2005]

7.    Bordi C., Falchetti A., Buffa R., Azzoni C., D’Adda T., Caruana P., Rindi G., Brandi M. L. Production of Basic Fibroblast Growth Factor by Gastric Carcinoid Tumors and Their Putative Cells of Origin. Hum Pathol. 25(2):175-180, 1994. [2.55; 2005]

8.    Falchetti A., Morelli A., Brandi M.L. Allelic loss on chromosome 11q12-13 in visceral lipoma and intestinal carcinoid from two patients with Multiple Endocrine Neoplasia Type 1. J Endocrinol Invest. 17(Suppl. 2 al #3):77, 1994. [1.496; 2005]

9.    Amorosi A., Nesi G., Spini S., Tonelli F., Falchetti A., Brandi M.L. Histologic Features of Parathyroid Hyperplasia in Multiple Endocrine Neoplasia Type I (MEN I). Diagnostic and Surgical Implications. Acta Chir. Austriaca, 26 (Suppl. 112); 13-15, 1994.

10.    Tonelli F. Spini S., Gabbrielli G., Falchetti A., Brandi M. L. The surgical treatment of hyperparathyroidism in multiple endocrine neoplasia type 1 (MEN 1) syndrome. Acta Chir. Austriaca, 26 (Suppl. 112); 26-28, 1994.

11.    Bordi C., Falchetti A., Azzoni T. et al. Lack of allelic loss at the men 1 gene locus in a non-endocrine adenocarcinoma of a patient with men 1 syndrome. Virchows Archiv. 426: 203-208, 1995. [2.224; 2005]

12.    Morelli A., Falchetti A., Weinstein L. et al. RFLPs analysis of human chromosome 11 region q13 in multiple symmetric lipomatosis and multiple endocrine neoplasia type 1-associated lipomas. Biochem Biophys Res Comm. 207(1):363-368, 1995. [3.0; 2005]

13.    Morelli A., Falchetti A., Castello R., et al. Genetic screening to identify the gene carrier in italian and german kindreds affected by multiple endocrine neoplasia type 1 (MEN 1) syndrome. J Endocrinol Invest. 18:329-335, 1995. [1.496; 2005]

14.    Fiorelli G., Gori F., Frediani U., Morelli A., Falchetti A., Benvenuti S., Masi L., Brandi M. L. Evidence for bioeffects of LY 139478 on the human preosteoclastic cell line FLG 29.1. Biochem Biophys Res Comm. 211(3):857-863, 1995. [3.0; 2005]

15.    Falchetti A., Tonelli F., Brandi M.L. Genetic aspects of molecular basis of parathyroid tissue growth. Italian J Min Electrolyte Metab. 9:73-78, 1995.

16.    Brandi M. L., Falchetti A., Tonelli F., Bordi C. Editorial: Are allelic losses at 11q13 universal in MEN 1 tumors? J. Clin. Endocrinol. Metab. 81(9):3162-3163, 1996. [6.02, 2005]

17.    Forti G., Falchetti A., Santoro S., Davis D. L., Wilson J. D., Russell D. W. Steroid 5à-reductase 2 deficiency: virilization in early infancy may be due to partial function of mutant enzyme. Clin. Endocrinol. 44:477-482, 1996. [3.412, 2005]

18.    Fiorelli G., Formigli L., Zecchi Orlandini S., Gori F., Falchetti A., Morelli A., Tanini A., Benvenuti S., Brandi M. L. Characterization and function of the receptor for IGF-1 in human preosteoclastic cells. Bone 18(3):269-276, 1996. [3.939, 2005]

19.    Morelli A., Falchetti A., Amorosi A., Tonelli F., Bearzi I., Ranaldi R., Tomassetti P., Brandi M. L. Clonal analysis by chromosome 11 microsatellite-PCR of microdissected parathyroid tumors from MEN 1 patients. Biochem. Biophys. Res. Comm., 227:736-742, 1996. [3.0, 2005]

20.    Bordi C., Falchetti A., Azzoni C., D’Adda T., Canavese G., Guariglia A., Santini D., Tomassetti P., Brandi M. L. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type 1. Am. J. Surg. Pathol. 21(9) :1075-1082, 1997. [4.377 2005]

21.    Benvenuti S., Masi L., Falchetti A., Mancini L., Formigli L., Zecchi S., Amorosi A., Tonelli F., Brandi M. L. HPE cells: A clonal endothelial cell line established from human parathyroid tissue (Human Parathyroid Cell Line). Endothelium 5:37-49, 1997. [2.343, 2005]

22.    Falchetti A., Morelli A., Amorosi A., Tonelli F., Fabiani S., Martineti V., Brandi M. L. Allelic loss in parathyroid tumors from MEN 1 homozygotes. J. Clin. Endocrinol. Metab. 82(7) :2278-2282, 1997. [6.02, 2005]

23.    Giorgi L., Fanfani E., Trovati F., Falchetti A., Novelli GP. Immediate-early genes expression in spinal cord as related to acute noxious stimulus. Int J Clin Pharmacol Res. 17(2-3): 59-61, 1997. [1.057, 2005]

24.    Falchetti A., Brandi M. L. Genetic testing for multiple endocrine neoplasias. Endocrine Related Cancer, 5:37, 1998. [4.905, 2005]

25.    Masi L., Becherini L., Gennari L., Colli E., Mansani R., Falchetti A., Cepollaro C., Gonnelli S., Tanini A., Brandi M.L.: Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. Bioch Bioph Res Comm 245:622, 1998. [3.0, 2005]

26.    L. Masi, L. Becherini, E. Colli, L. Gennari, R. Mansani, A. Falchetti, A.M. Becorpi, C. Cepollaro, S. Gonnelli, A. Tanini, M.L. Brandi: Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal Italian women. Biochem Biophys Res Comm, 248: 190, 1998. [3.0, 2005]

27.    L. Gennari, L. Becherini, R. Mansani, L. Masi, A. Falchetti, A.M. Morelli, E. Colli, S. Gonnelli, C. Cepollaro, M.L. Brandi: Fok I polymorphhism of the vitamin D receptor gene, bone mineral density and osteoporotic fractures in postmenopausal Italian women. J Bone Min Res. 14(8):1379-86, 1999. [6.527, 2005]

28.    Falchetti A, Becherini Lucia, Martineti Valentina, Morelli Annamaria, Benvenuti Susanna, Picariello Lucia, Gennari Luigi, Lampugnani Rinaldo, Bordi Cesare, Brandi Maria Luisa. Telomerase Repeat Amplification Protocol (Trap): A New Molecular Marker For Parathyroid Carcinoma. Biochem Biophys Res Comm. 26(5):252-5, 1999. [3.0, 2005]

29.    Morelli A., Falchetti A., Martineti V., Becherini L., Mark M., Friedman E., Brandi M. L. MEN1 gene mutation analysis in Italian patients affected by Multiple Endocrine Neoplasia type 1 syndrome. Eur J Endocrinol. 142(2):131-137, 2000. [2.962, 2005]

30.    Becherini L., Gennari L., Masi L., Mansani R. Massart F., Morelli A., Falchetti A., Gonnelli S., Fiorelli G., Tanini A., Brandi M. L. Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alfa gene and their relationship to bone mass variation in postmenopausal women. Human Molecular Genetics 9(12):2043-2050, 2000. [7.764, 2005]

31.    Picariello L., Benvenuti S., Recenti R., Formigli L., Falchetti A., Morelli A., Masi L., Cicchi P., Tonelli F., Brandi M.L. Microencapsulation of human parathyroid cells: an “in vitro” study. Journal of Surgical Research 96(1):81-89, 2001. [1.956, 2005]

32.    Masi L., Becherini L., Gennari L., Amedei A., Colli E., Falchetti A., Farci M., Silvestri S., Gonnelli S., Brandi M. L. Polymorphism of the Aromatase gene in postmenopausal women: distribution and correlation with bone mass and fracture risk. J. Clin. Endocrinol. Metab, 86(5): 2263-2269, 2001. [6.02, 2005]

33.    Mark M., Morelli A., Brandi M. L., Falchetti A., Olchovski D., Arnaldi G., Mantero F., Friedman E. Somatic mutation analysis of the MEN1 gene in adrenocrotical tumors using denaturing gradient gel electrophoresis (DGGE). Journal of Endocrine Genetics, 2:21-27, 2001.

34.    Brandi ML., Gennari L., Matucci Cerinic M., Becherini L., Falchetti A., Masi L., Gennari C., Reginster JY. Genetic markers of osteoarticular disorders: facts and hopes. Arthritis Research, 3:270-280, 2001. [2.965, 2005]

35.    Morelli A., Falchetti A., Brandi ML. Gene mutations in Multiple Endocrine Neoplasia type 1. Topical Endocrinology, 18:6-9, July 2001.

36.    L. Gennari, L. Becherini, A. Falchetti, L., Masi, F. Massart, Brandi M.L. Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. Journal of Steroid Biochemistry & Molecular Biology 81(1):1-24, 2002. [2.866, 2005]

37.    Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001 Dec;86(12):5658-71. [6.02, 2005]

38.    Falchetti A. Genetics of osteoarticular disorders, Florence, Italy, 22-23 February 2002. Arthritis Res 4(5):326-31, 2002. [2.965, 2005]

39.    Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F, Malentacchi C, Porfirio B, Adamo D, Terranegra A, Falchetti A, Cusi D, Bianchi G, Brandi ML. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 13(10):2517-23, 2002. [7.240, 2005]

40.    Massart F, Becherini L, Marini F, Noci I, Piciocchi L, Del Monte F, Masi L, Falchetti A, Tanini A, Scarselli G, Brandi L. Analysis of estrogen receptor (ERa and ERb) and progesterone receptor (PR) polymorphisms in uterine leiomyomas. Med Sci Monit 9(1):BR25-30, 2003.

41.    Cioppi F, Falchetti A, Masi L, Brandi ML. Dynamic investigation for evaluation of calcium metabolism and parathyroid function. J Endocrinol Invest. 2003;26(7 Suppl):83-91. [1.496, 2005]

42.    Falchetti A., M. Di Stefano, F. Marini, F. Del Monte, C. Mavilia, D. Strigoli, M. L. De Feo, G. Isaia, L. Masi, A. Amedei, F. Cioppi, V. Ghinoi, S. Maddali Bongi, G. Di Fede, C. Sferrazza, G. B. Rini, D. Melchiorre, M. Matucci-Cerinic and M. L. Brandi. Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian series of patients affected by Paget’s disease of bone (PDB). Journal of Bone and Mineral Research 19(6):1013-7, 2004. [6.527, 2005]

43.    Falchetti A. "Calcium agonists in hyperparathyroidism" Invited review Expert Opin Investig Drugs. 2004 Mar;13(3):229-44. [3.267, 2005]

44.    Brandi ML, Falchetti A. Genetics of primary hyperparathyroidism. Urol Int. 2004;72 Suppl 1:11-6. [0.585, 2005]

45.    Gennari L, Masi L, Merlotti D, Picariello L, Falchetti A, Tanini A, Mavilia C, Del Monte F, Gonnelli S, Lucani B, Gennari C, Brandi ML. A Polymorphic CYP19 TTTA Repeat Influences Aromatase Activity and Estrogen Levels in Elderly Men: Effects on Bone Metabolism. J Clin Endocrinol Metab. 2004 Jun;89(6):2803-10. [6.02, 2005]

46.    Falchetti A., Vezzosi G., Gambaro G. Genetics of primary hypercalciuria. Clinical Cases in Mineral and Bone Metabolism. 2004, 1:27-34.

47.    Croppi E., Vitale C., Bevilacqua M., Borghi L., Caudarella R., Falchetti A., Gambero G., Marangella M., Trinchieri A., Vezzosi G., Brandi ML. Consensus statement on diagnosis of primary hypercalciuria. Clinical Cases in Mineral and Bone Metabolism. 2004, 1:73-75.

48.    Lucia Bacciottini, Annalisa Tanini, Alberto Falchetti, Laura Masi, Francesco Franceschelli, Barbara Pampaloni, Gianluca Giorgi, Maria Luisa Brandi. Calcium bioavailability from a calcium-rich mineral water, with some observations on method. J Clin Gastroenterol. 2004; 38(9):761-6. [2.258, 2005]

49.    Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med. 2005 Jan;257(1):38-49. [4.04, 2005]

50.    Falchetti A, Marini F, Masi L, Brandi ML Genetic aspects of Paget’s disease of bone. Clinical Cases in Mineral and Bone Metabolism. 2004, I(3):191-202.

51.    Ferolla P, Falchetti A, Filosso P, Tomassetti P, Tamburrano G, Avenia N, Daddi G, Puma F, Ribacchi R, Santeusanio F, Angeletti G, Brandi ML. Thymic Neuroendocrine Carcinoma (Carcinoid) in MEN1 Syndrome: the Italian series. J Clin Endocrinol Metab. 2005 May;90(5):2603-9. [6.02, 2005]

52.    Ulivieri FM, Falchetti A, Marini F, Brandi ML, Piodi LP, Crespi A, Verdoia C, Gerundini P. A familial case of Paget’s disease of bone with mutation at exon 8 of the sequestosome 1 (SQSTM1/p62) gene. Clinical Cases in Mineral and Bone Metabolism 2004, I(3): 231-33.

53.    Falchetti A, Franchi A, Bordi C, Mavilia C, Masi L, Cioppi F, Recenti R, Picariello L, Marini F, Del Monte F, Ghinoi V, Martineti V, Tanini A, Brandi ML. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res. 2005 Mar;20(3):410-8. [6.527, 2005]

54.    V Martineti, L Picariello§, I Tognarini, S Carbonell Sala, A Gozzini, C Azzari, C Mavilia, A Tanini, A Falchetti, G Fiorelli, F Tonelli And M L Brandi. ERb is a potent inhibitor of cell proliferation in HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Rel Cancer 12(2):455-69, 2005. [4.905, 2005]

55.    Falchetti A., Marini F., Tonelli F, Brandi M. L. Lessons from genes mutated in multiple endocrine neoplasia (MEN) syndromes. Ann. Endocrinol 2005; 66, 3:195-205. [0.506, 2005]

56.    Falchetti A., Di Stefano M., Marini F., Del Monte F., Gozzini A., Masi L., Tanini A., Amedei A., Carossino A., Isaia G. and. Brandi M. L. Segregation of M404V mutation of p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget’s disease of bone in an Italian family. Arthritis Res. & Therapies 2005; 7(6):R1289-95. [2.965, 2005]

57.    A. Falchetti, F. Marini, F. Del Monte et al. Results of a national survey on multiple endocrine neoplasia syndrome type 1 in Italy: a macroaggregate analysis. Clinical Cases in Mineral and Bone Metabolism 2005, II(1): 29-35.

58.    L Gennari, A. Falchetti, Bandini S. et al. Genetic polymorphisms of vitamin D receptor amd calcium sensing receptor gene in uremic secondary hyperparathyroidism: a multicentric Italian study. Clinical Cases in Mineral and Bone Metabolism 2005, II(1): 37-41.

59.    A. Falchetti, Gozzini A., Masi L et al. Allelic loss at the vitamin D receptor (VDR) locus in parathryoid tissue from one patient affected by refractory uremic. Clinical Cases in Mineral and Bone Metabolism 2005, II(1): 53-55.

60.    Francesco Tonelli, Geri Fratini., Gabriella Nesi, Maria Silvia Tommasi., Giacomo Batignani, Alberto Falchetti, and Maria Luisa Brandi. Pancreatectomy in Multiple Endocrine Neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Annals of Surgery 257(1):38-49, 2005. [6.328, 2005]

61.    Carbonell Sala S, Masi L, Marini F, Del Monte F, Falchetti A, Franceschelli F, Brandi ML. Genetics and pharmacogenetics of osteoporosis. J Endocrinol Invest. 2005;28(10 Suppl):2-7. [1.496, 2005]

62.    Ralston SH, Uitterlinden AG, Brandi ML, Balcells S, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Scollen S, Bustamante M, Husted LB, Carey AH, Diez-Perez A, Dunning AM, Falchetti A, Karczmarewicz E, Kruk M, Leeuwen JP, Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, Monte FD, Pols HA, Reeve J, Reid DM, Renner W, Rivadeneira F, Schoor NM, Sherlock RE, Ioannidis JP. Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study. PLoS Med. 2006 Feb 21;3(4): e90. [13.800, 2006]

63.    Nuzzo V, Tauchmanova L, Falchetti A, Faggiano A, Marini F, Piantadosi S, Brandi ML, Leopaldi L, Colao A. MEN1 family with a novel frameshift mutation. J Endocrinol Invest. 2006 May; 29(5):450-6. [1.496, 2005]

64.    Tonelli F, Fratini G, Nesi G, Tommasi MS, Batignani G, Falchetti A, Brandi ML. Pancreatectomy in Multiple Endocrine Neoplasia Type 1-Related Gastrinomas and Pancreatic Endocrine Neoplasias. Ann Surg. 2006 Jul; 244(1):61-70. [6.328, 2005]

65.    G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard, W. W. der Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth, M. Körner, J.M. Lopes, A-M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J-Y. Scoazec, B. Wiedenmann and all other Frascati Consensus Conference participants. TNM STAGING OF FOREGUT (NEURO)ENDOCRINE TUMORS: a consensus proposal including a grading system. Virchows Arch. 449(4):395-401, 2006. [2.224, 2005]

66.    Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, Brandi ML. Multiple Endocrine Neoplasia Type 1. Orphanet J Rare Dis. 2006 Oct 2;1(1):38 [Epub ahead of print]. [1.030, 2006]

67.    Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Tognarini I, Luzi E, Brandi ML. Multiple Endocrine Neoplasia Type 2. Orphanet J Rare Dis. 2006 Nov 14:1-45 [Epub ahead of print]. [1.030, 2006]

68.    Falchetti A. and Maria Luisa Brandi. Hereditary Hyperparathyroidism. Clinical Cases in Mineral and Bone Metabolism, 2006; 3(2):141-149.

69.    Brandi ML and Falchetti A. What is the relationship between Paget's disease of bone and hyperparathyroidism? Journal of Bone and Mineral Research 2006 Dec;21 Suppl 2:P69-74. [6.527, 2005]

70.    A. Falchetti, C. Sferrazza, C. Cepollaro, A. Gozzini, F. Del Monte, L. Masi, N. Napoli, G. Di Fede, V. Cannone, G. Cusumano, M. C. Pandolfo, G. B. Rini, A. Tanini and M. L. Brandi. FokI polymorphism of vitamin d receptor gene correlates with dual x-ray absorptiometry, quantitative ultrasound and bone turnover markers in an italian female population from Lampedusa island. Calcif Tissue Int. 2007 Jan;80(1):15-20. [2.487, 2005]

71.    Cepollaro C, Lauretani F, Gozzini A, Masi L, Falchetti A, Del Monte F, Carbonell-Sala S, Tanini A, Corsi AM, Bandinelli S, Ferrucci L, Brandi ML. Relationship of Volumetric Bone Mineral Density and Structural Parameters with ERalpha Gene Polymorphisms. Calcif Tissue Int. 2007 May;80(5):307-15. Epub 2007 May 16. [2.487, 2005]

72.    Adami S, Bartolozzi P, Brandi ML, Falchetti A, Filipponi P, Gonnelli S, Bianchi G, Isaia GC, Nuti R. Italian guidelines for the diagnosis and treatment of Paget's disease of bone. Reumatismo. 2007 Apr-Jun;59(2):153-68.

73.    Masi L, Falchetti A, Brandi ML. Osteonecrosis in genetic disorders. Clinical Cases in Mineral and Bone Metabolism, 2007; 4(1):27-29.

74.    Falchetti A, Masi L, Brandi ML. Thiazolidinediones and bone. Clinical Cases in Mineral and Bone Metabolism, 2007; 4(2):103-105.

75.    Bacciottini L, Falchetti A, Pampaloni B, Bartolini E, Carossino A, Brandi ML. Phytoestrogens: food or drug? Clinical Cases in Mineral and Bone Metabolism, 2007; 4(2):123-130.

76.    Masi L, Del Monte F, Gozzini A., De Feo ML, Gheri RG, Neri A, Falchetti A, Amedei A, Imbraco R, Mavilia C, Tanini A, Brandi ML. A novel polymorphism at the GNAS1 gene associated with low circulating calcium levels. Clinical Cases in Mineral and Bone Metabolism, 2007; 4(2):139-145.

77.    Masi L, Maddali Bongi S, Angotti C, Del Monte F, Carbonell Sala S, Basetti A, Amedei A, Falchetti A, Brandi ML. The role of osteoprotegerin (OPG) and estrogen receptor (ER-a) gene polymorphisms in rheumatoid arthritis. Clinical Cases in Mineral and Bone Metabolism, 2007; 4(2):156-160.

78.    F Tonelli, T Marcucci; G Fratini; MS Tommasi; A Falchetti, ML Brandi. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg. 2007 Dec;246(6):1075-82. [6.328, 2005]

79.    Laura Masi, Francesca Del Monte, Alessia Gozzini, Maria Laura De Feo, Riccardo Gionata Gheri, Annasilvia Neri, Alberto Falchetti, Antonietta Amedei, Rosario Imbriaco, Carmelo Mavilia, Annalisa Tanini, Maria Luisa Brandi. A novel polymorphism at the GNAS1 gene associated with low circulating calcium levels. Clinical Cases in Mineral and Bone Metabolism 2007; 4(2): 139-145.

80.    Lucia Bacciottini, Alberto Falchetti, Barbara Pampaloni, Elisa Bartolini, Anna Maria Carossino, Maria Luisa Brandi. Phytoestrogens: food or drug? Clinical Cases in Mineral and Bone Metabolism 2007; 4(2): 123-130.

81.    Laura Masi, Susanna Maddali Bongi, Chiara Angotti, Francesca Del Monte, Silvia Carbonell Sala, Massimo Basetti, Antonietta Amedei, Alberto Falchetti, Maria Luisa Brandi. The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis. Clinical Cases in Mineral and Bone Metabolism 2007; 4(2): 156-160.

82.    Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, Scollen S, Lips P, Lorenc R, Obermayer-Pietsch B, Reid DM, Armas JB, Arp PP, Bassiti A, Bustamante M, Husted LB, Carey AH, Pérez Cano R, Dobnig H, Dunning AM, Fahrleitner-Pammer A, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, Masi L, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, Mosekilde L, Nogués X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Ioannidis JP; APOSS investigators; DOPS investigators; EPOS investigators; EPOLOS investigators; FAMOS investigators; LASA investigators; ERGO investigators; GENOMOS Study. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone. 2008 May;42(5):969-81. [3.939, 2005]

83.    Villa C, Magri F, Morbini P, Falchetti A, Scagnelli P, Lovati E, Locatelli D, Canevari FR, Necchi V, Gabellieri E, Guabello G, Chiovato L, Solcia E. Silent Familial Isolated Pituitary Adenomas: Histopathological and Clinical Case Report. Endocr Pathol. 2008 Mar 4. [Epub ahead of print]. [1.099, 2005]

84.    Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML. Multiple endocrine neoplasms. Best Pract Res Clin Rheumatol. 2008 Mar;22(1):149-63. [1.904, 2005]

85.    van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O, Lorenc R, Obermayer-Pietsch B, Ohlsson C, Pettersson U, Reid DM, Rousseau F, Scollen S, Van Hul W, Agueda L, Akesson K, Benevolenskaya LI, Ferrari SL, Hallmans G, Hofman A, Husted LB, Kruk M, Kaptoge S, Karasik D, Karlsson MK, Lorentzon M, Masi L, McGuigan FE, Mellström D, Mosekilde L, Nogues X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Weber K, Ioannidis JP, Uitterlinden AG; GENOMOS Study. Collaborators Falchetti A et al. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008 Mar 19;299(11):1277-90. [23.332, 2005]

86.    Falchetti A, Cilotti A, Vaggelli L, Masi L, Amedei A, Cioppi F, Tonelli F, Brandi ML. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab. 2008 Jun;4(6):351-7. [3.678, 2007]

87.    Marini F, Falchetti A, Silvestri S, Bagger Y, Luzi E, Tanini A, Christiansen C, Brandi ML. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin. 2008 Sep;24(9):2609-15. [2.945, 2005]

88.    F. Marini, S. Carbonell Sala, A. Falchetti, D. Caramelli, M.L. Brandi. The genetic ascertainment of multiple endocrine neoplasia type 1 (MEN1) syndrome by ancient DNA analysis. J Endocrinol Invest. 2008 Oct;31(10):905-9. [1.496, 2005]

89.    D Najat, T Garner, T Hagen, B Shaw, PW Sheppard, A Falchetti, F Marini, ML Brandi, JE Long, JR Cavey, MS Searle, R Layfield. Characterisation of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J Bone Miner Res. 2008 Dec 2, 24(4):632-42. [6.527, 2005]

90.    Falchetti A, Di Stefano M, Marini F, Ortolani S, Ulivieri FM, Bergui S, Masi L, Cepollaro C, Benucci M, Di Munno O, Rossini M, Adami S, Del Puente A, Isaia G, Torricelli F, Brandi ML, on behalf of the GenePage Project. Genetic epidemiology of Paget’s disease of bone in Italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget’s disease of bone. Calcif Tissue Int. 2009 Jan;84(1):20-37. [2.487, 2005]

91.    Falchetti A., Marini F., Giusti F., Cavalli L., Cavalli T., Brandi M. L. DNA-based Test: When and Why to apply it to Primary Hyperparathyroidism Clinical Phenotypes. J Intern Med. 2009 Jul;266(1):69-83. [4.04, 2009]

92.    Alberto Falchetti and Maria Luisa Brandi. MEN1-related states, MEN1 variants, MEN1 phenocopies: are they only a nosologic issue? J Clin Endocrinol Metab. 2009 May; 94(5):1518-20. [6.02, 2008]

93.    Masi L, Gozzini A, Franchi A, Campanacci D, Amedei A, Falchetti A, Franceschelli F, Marcucci G, Tanini A, Capanna R, Brandi ML. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis. J Bone Joint Surg Am. 2009 May;91(5):1190-8. [2.444, 2006]

94.    Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML. Surgical Approach in Hereditary Hyperparathyroidism. Endocr J. 2009;56(7):827-41. [1.600, 2008]

95.    Laura Papi, Domenico Palli, Laura Masi, Anna Laura Putignano, Caterina Congregati, Ines Zanna, Francesca Marini, Francesca Giusti, Ettore Luzi, Francesco Tonelli, Maurizio Genuardi, Maria Luisa Brandi, Alberto Falchetti. Germline mutations in MEN1 and BRCA1 genes in a female subject with familial Multiple Endocrine Neoplasia type 1 and inherited breast/ovarian cancer syndromes: a case report. Cancer Genet Cytogenet. 2009 Nov;195(1):75-9. [1.529, 2003]

96.    Falchetti Alberto, Marini Francesca, Luzi Ettore, Giusti Francesca, Cavalli Loredana, Cavalli Tiziana, Brandi Maria Luisa. Multiple Endocrine Neoplasia Type 1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009 Dec;11(12):825-35. [3.716, 2008]

97.    Antonio Cilotti, Alberto Falchetti. Male osteoporosis and androgenic therapy: from testosterone to SARMs. Clinical Cases in Mineral and Bone Metabolism 2009; 6(3): 229-233.

98.    Loredana Cavalli, Tiziana Cavalli, Gemma Marcucci, Alberto Falchetti, Laura Masi, Maria Luisa Brandi. Biological effects of various regimes of 25-hydroxyvitamin D3 (calcidiol) administration on bone mineral metabolism in postmenopausal women. Clinical Cases in Mineral and Bone Metabolism 2009; 6(2): 169-173.

99.    Edwin Jobany Parra Prada, Khodr Haidar Hassan, Maria Luisa Brandi, Alberto Falchetti. Polyostotic form of fibrous dysplasia in a 13 years old Colombian girl showing clinical and biochemical response to neridronate intravenous therapy. Clinical Cases in Mineral and Bone Metabolism 2009; 6(3): 264-265.

100.    Vincenzo Nuzzo, T. Ferrara, Alfonso Zuccoli, Raffaella Brunetti-Pierri, Roberto De Rosa, Alberto Falchetti, R. Franco, and Nicola Brunetti-Pierri. Infiltrating giant cell tumor in a case of Paget’s disease of bone. Arch Osteoporos. 2009 December; 4(1-2): 91–94.

101.    Francesca Giusti, Alberto Falchetti, Francesco Franceschelli, Francesca Marini, Annalisa Tanini and Maria Luisa Brandi Thyroid Cancer: Current Molecular Perspectives. J Oncol. 2010; 2010:351679.

102.    Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Verga U, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R; ItaMEN network. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010 August; 163(2):301-8. [3.539, 2009]

103.    Falchetti A, Masi L, Brandi ML. Paget's disease of bone: there's more than the affected skeletal--a clinical review and suggestions for the clinical practice. Curr Opin Rheumatol. 2010 Jul;22(4):410-23. [4.600, 2010]

104.    Maria Giovanna Filippella, Antongiulio Faggiano, Alberto Falchetti, Annamaria Colao, Carlo Rosa, Carlo Poti, Corrado Musso, Giulio Doveri, and Maria Luisa Brandi. Risk of fractures and bone abnormalities in postmenopausal women with type 2 diabetes mellitus. Clin Cases Miner Bone Metab. 2010 May–Aug; 7(2): 126–129.

105.    Roberta Cosso, Vincenzo Nuzzo, Alfonso Zuccoli, Maria Luisa Brandi, and Alberto Falchetti. Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent. Clin Cases Miner Bone Metab. 2010 May–Aug; 7(2): 145–152.

106.    Genetic aspects of the Paget's disease of bone: concerns on the introduction of DNA-based tests in the clinical practice. Advantages and disadvantages of its application. Falchetti A, Marini F, Masi L, Amedei A, Brandi ML. Eur J Clin Invest. 2010 Jul;40(7):655-67. [2.643, 2009]

107.    Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients. Luzi E, Marini F, Tognarini I, Carbonell Sala S, Galli G, Falchetti A, Brandi ML. Cancer Gene Ther. 2010 Nov;17(11):814-25. [3.126, 2009]

108.    Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how. Falchetti A. F1000 Med Rep. 2010 Feb 24;2. pii: 14.

109.    LRP5 gene polymorphism and cortical bone. Lauretani F, Cepollaro C, Bandinelli S, Cherubini A, Gozzini A, Masi L, Falchetti A, Del Monte F, Carbonell-Sala S, Marini F, Tanini A, Corsi AM, Ceda GP, Brandi ML, Ferrucci L. Aging Clin Exp Res. 2010 Aug;22(4):281-8. [1.26, 2009].

110.    Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Marini F, Tonelli P, Cavalli L, Cavalli T, Masi L, Falchetti A, Brandi ML. Front Biosci (Elite Ed). 2011 Jan 1;3364-70. [3.603, 2009]

111.    MEN syndromes. Falchetti A. Tumori. 2010 Sep-Oct;96(5):823-6. [0.86, 2009]

112.    Bargellini T, Cantelli G, Bruscino A, Falchetti A, Giusti F, Brandi ML, Valeri A. Left laparoscopic adrenalectomy for pheochromocytoma in MEN 2B: case report. G Chir. 2011 Mar;32(3):132-4.

113.    The Genetic Determinants of Paget's Disease (GDPD) Consortium, Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, Montes JD, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet. 2011 May 29;43(7):685-9. [34.284, 2010].

114.    Falchetti A, Cavalli L, Cavalli T, Giusti F, Marcucci G, Marini F, Brandi ML. Molecular diagnosis of parathyroid carcinoma: a reality in the near future. Expert Opin Med Diagn. 2012 Jan;6(1):27-37.

115.    Falchetti A, Gozzini A, Terranegra A, Soldati L, Vezzoli G, Leoncini G, Giusti F, Franceschelli F, Masi L, Tanini A, Cavalli L, Brandi ML. A novel germline inactivating mutation in the CaSR gene in an italian kindred affected by Familial Hypocalciuric Hypercalcemia. Eur J Endocrinol. 2012 Feb 7. [Epub ahead of print]. [3.9, 2010].

116.    Ettore Luzi, Francesca Marini, Isabella Tognarini, Gianna Galli, Alberto Falchetti and Maria Luisa Brandi. The regulatory network menin-microRNA 26a as possible target for a RNA-based therapy of bone diseases. Nucleic Acid Ther. 2012 Apr;22(2):103-8. [2.9, 2010].

117.    Malavolta N, Rossi E, Buffa A, Falchetti A. Fragility fractures: clinical and therapeutic aspects. J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):761-9. [2.04, 2016].

118.    Roberta Cosso & Alberto Falchetti (2016): Vitamin K and bone metabolism: the myth and the truth, Expert Review of Precision Medicine and Drug Development, DOI: 10.1080/23808993.2016.1174061.

119.    Falchetti A. Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old. F1000Res. 2017, Jan 24;6.

120.    Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M, Falchetti A, Chiodini I. Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. J Am Geriatr Soc. 2018 Jan 24. doi: 10.1111/jgs.15250. [Epub ahead of print] [4.388, 2017].

121.Roberto Cesareo, Roberto Attanasio, Marco Caputo, Roberto Castello, Iacopo Chiodini, Alberto Falchetti, Rinaldo Guglielmi, Enrico Papini, Assunta Santonati, Alfredo Scillitani, Vincenzo Toscano, Vincenzo Triggiani, Fabio Vescini, Michele Zini and on behalf of AME and Italian AACE Chapter. Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients 2018, 10, 546; doi:10.3390/nu10050546. [I. F. 4,187].

122. Cosso Roberta and Falchetti Alberto. Mitochondriopathies and bone health. Journal of Trends in Biomedical Research 2018 Volume 1(1): 1-7. doi:10.15761/JTBR.1000101.

123. Alberto Falchetti and Roberta Cosso. The interaction between vitamin C and bone health: a narrative review. Expert Review of Precision Medicine and Drug Development https://doi.org/10.1080/23808993.2018.1482211.

124. Palermo A, Capoluongo E, Del Toro R, Manfrini S, Pozzilli P, Maggi D, Defeudis G, Pantano F, Coppola R, Di Matteo FM, Raffaelli M, Concolino P, Falchetti A. A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins. Hormones (Athens). 2018 Sep;17(3):427-435. [I. F. 1,237].

125. Falchetti A. Genetics of parathyroids disorders: overview. Best Practice & Research Clinical Endocrinology & Metabolism (accepted for publication). [I. F. 4,791].

126. Eller-Vainicher C, Falchetti A. Management of familial Hyperparathyroid syndromes: MEN1, MEN2, HPT-Jaw tumour, FHH, neonatal severe hyperparathyroidism, familial isolated hyperparathyroidism. Best Practice & Research Clinical Endocrinology & Metabolism (accepted for publication). [I. F. 4,791].

127. Vescini F, Falchetti A, Tonelli V, Carpentieri M, Cipri C, Cosso R, Kara E, Triggiani V, Grimaldi F. Mazabraud's Syndrome: A Case Report And Up-To-Date Literature Review. Endocr Metab Immune Disord Drug Targets. 2018 Dec 25. doi: 10.2174/1871530319666181226103700 [I. F. 2.013].

128. Gennari L, Rendina D, Falchetti A, Merlotti D. Paget's Disease of Bone. Calcif Tissue Int. 2019 Jan 23. doi: 10.1007/s00223-019-00522-3. [I. F. 3,293].

129. Merlotti D, Falchetti A, Chiodini I, Gennari L. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019 Mar 11:1-7. [I. F. 3.469].

130. Eller-Vainicher C, Falchetti A, Gennari L, Cairoli E, Bertoldo F, Vescini F, Scillitani A, Chiodini I. DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders. Eur J Endocrinol. 2019 Apr 1. pii: EJE-18-0991.R1. [I. F. 4,333]

131. Cesareo R, Falchetti A, Attanasio R, Tabacco G, Naciu AM, Palermo A. Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol? Nutrients. 2019 May 6;11(5). pii: E1016. [I. F. 4,196]

132. Chiodini I, Gaudio A, Eller-Vainicher C, Morelli V, Aresta C, Zhukouskaya VV, Merlotti D, Orsi E, Barbieri AM, Fustinoni S, Polledri E, Gennari L, Falchetti A, Carnevale V, Persani L, Scillitani A. Cortisol secretion, sensitivity, and activity are associated with hypertension in postmenopausal eucortisolemic women. J Clin Endocrinol Metab. 2019 May 21. pii: jc.2019-00037. doi: 10.1210/jc.2019-00037. [I. F. 59255]

Research Interest: Sports Injuries.,Sports and Health.,Sarcopenia.,Sports nutrition

Research Interest: Diabetes experimental and clinical and gastroenterology and neuroendocrine tumors

Research Interest: Thyroid,diabetes and other endocrine diseases

Research Interest: Aldosterone, mineralocorticoids, mineralocorticoid receptor, gene expression, miRNAs, animal models, microarrays, renin-angiotensin system, steroid hormones, nuclear receptors, hypertension, intracellular signaling.